Efficacy and safety of ruxolitinib vs best available therapy for polycythemia vera: An updated systematic review and meta‐analysis

Ruxolitinib, a JAK1/JAK2 inhibitor, has been shown to have lower thromboembolism rates compared to placebo in polycythemia vera (PV) patients. This meta‐analysis evaluates ruxolitinib's efficacy and safety against best available therapy (BAT) in patients with PV and in hydroxyurea‐resistant/int...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	APMIS : acta pathologica, microbiologica et immunologica Scandinavica microbiologica et immunologica Scandinavica, 2024-11, Vol.132 (11), p.775-786
Hauptverfasser:	Roca Mora, M. Meritxell, Afzal, Farhan, Guimaraes, Catharina Ribeiro, Cunha, Luisa Marin, Godoi, Amanda, Marcolin, Patrícia, Valenzuela S, Andrés
Format:	Artikel
Sprache:	eng
Schlagworte:	Anemia Cancer Effectiveness Hematocrit Herpes zoster Humans Hydroxyurea Hydroxyurea - adverse effects Hydroxyurea - therapeutic use JAK inhibitor Janus kinase Janus Kinase 1 - antagonists & inhibitors Janus kinase 2 Janus Kinase 2 - antagonists & inhibitors Literature reviews Meta-analysis myeloproliferative neoplasm Neoplasms Nitriles - therapeutic use Polycythemia Polycythemia vera Polycythemia Vera - drug therapy Pyrazoles - adverse effects Pyrazoles - therapeutic use Pyrimidines - therapeutic use ruxolitinib Safety Skin cancer Skin resistance Subgroups Thromboembolism Treatment Outcome
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Beschreibung
Zusammenfassung:	Ruxolitinib, a JAK1/JAK2 inhibitor, has been shown to have lower thromboembolism rates compared to placebo in polycythemia vera (PV) patients. This meta‐analysis evaluates ruxolitinib's efficacy and safety against best available therapy (BAT) in patients with PV and in hydroxyurea‐resistant/intolerant PV patients. A comprehensive literature search was conducted up to November 2023. We compared ruxolitinib and BAT for efficacy and safety endpoints. Six studies involving 1061 patients were analyzed, with 620 on BAT and 441 on ruxolitinib. Ruxolitinib showed higher hematocrit control (p = 0.015) and treatment response (p = 0.04) compared to BAT. It also significantly improved Myeloproliferative Neoplasms‐Symptom Assessment Form scores (MPN‐SAF) (p
ISSN:	0903-4641 1600-0463 1600-0463
DOI:	10.1111/apm.13472